CG Labz
Peptide Library / Metabolic / Weight Management

CagriSema (Cagrilintide + Semaglutide)

Amylin + GLP-1 Blend

CagriSema (Cagrilintide + Semaglutide) Research Protocol

Complete Research Guide 4 min read1 peer-reviewed references

Quickstart Overview

CagriSema is a fixed research blend of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist). The two hormones act on separate satiety circuits, and the combination produced greater weight reduction than either component alone in clinical studies.

Reconstitution
Add 2.0 mL bacteriostatic water to the 10 mg (5+5) vial → 5 mg/mL total
Blend
Cagrilintide 5 mg + Semaglutide 5 mg
Measuring Reference
At 5 mg/mL: 1 mg total = 0.2 mL = 20 units
Frequency
Once weekly
Route (studies)
Subcutaneous
Half-life
~7 days (both components)

Scientific Data

Molecular Formula
—
Molecular Weight
—
Sequence
Cagrilintide 5 mg + Semaglutide 5 mg
Sequence Length
27
CAS
Research compound
Peptide Family
Blend
Half-life
Refer to published literature
Solubility
Bacteriostatic water, sterile saline
Storage
Lyophilized: -20°C. Reconstituted: 2–8°C, use within 2–4 weeks.
Appearance
White lyophilized powder
Standard: 10 mg vial · 2 mL diluent

Dosing & Reconstitution Guide

Interactive Reconstitution
Adjust vial size, diluent and target dose. Results update live.
Full Precision Calculator →
Concentration
5.00 mg/mL
Draw Volume
0.100 mL
Syringe Units
10.0 U
Doses / Vial
20

Units assume a U-100 insulin syringe (100 units = 1 mL). Fixed 1:1 blend; titrate the combined dose slowly to manage GI tolerability.

Frequency: Once weekly

Reconstitution Steps

  1. 1Allow the lyophilized vial and bacteriostatic water to reach room temperature (~15 min).
  2. 2Swab both vial stoppers with a fresh 70% isopropyl alcohol pad and let them dry.
  3. 3Draw 2.0 mL of bacteriostatic water into a mixing syringe.
  4. 4Insert at an angle and let the water run slowly down the glass wall — never directly onto the powder.
  5. 5Gently swirl (do not shake) until the solution is completely clear.
  6. 6Label with date and concentration (mg/mL) and refrigerate at 2–8 °C immediately.

Supplies Needed

Planning example for a 20-week protocol at approximately 500 mcg per day.

Peptide (10 mg vials)
Estimate vials from total mass: 500 mcg/day × 140 days.
Bacteriostatic Water
One 10–30 mL vial typically covers a full cycle.
Insulin Syringes (U-100)
One per administration (29–31 G, 0.3–0.5 mL).
Alcohol Swabs
Two per administration (vial + site).
Sharps Container
Required for safe disposal.

Protocol Overview

Goal
Model combined amylin + GLP-1 satiety effects on body weight.
Schedule
Weekly, titrated.
Dose Range
Per combined-dose titration schedule.

Dosing Protocol

Weeks 1–4
Low combined starting dose, once weekly
Titration
Step up every 4 weeks per tolerability
Maintenance
Target combined dose as tolerated
Frequency
Once weekly
Timing
Same day weekly
Note
Blend ratio is fixed per vial — see label

Storage Instructions

Lyophilized
−20 °C long term (18–24 months); stable at room temperature for short transit.
Reconstituted
2–8 °C refrigerated; use within 4 weeks.
Light
Protect from direct light; keep in the original carton.
Freeze/Thaw
Avoid repeat freeze–thaw cycles after reconstitution.

Important Notes

  • GI tolerability is the main limiter; titrate the combined dose gradually.
  • Shares the incretin boxed-warning class (rodent thyroid C-cell tumours).

How This Works

Semaglutide activates GLP-1 receptors (insulin secretion, glucagon suppression, central satiety, delayed gastric emptying) while cagrilintide activates amylin/calcitonin receptors in the hindbrain (satiety and gastric emptying via a distinct pathway). Dual activation of complementary appetite circuits yields additive reductions in food intake and body weight, with both components acylated for once-weekly dosing.

Potential Benefits & Side Effects

Reported in research
  • Greater weight loss than semaglutide or cagrilintide alone in trials
  • Dual satiety-pathway activation (amylin + GLP-1)
  • Improved glycemic markers
  • Once-weekly convenience
Possible considerations
  • Nausea, vomiting and GI effects (dose-dependent)
  • Injection-site reactions
  • Appetite suppression may require attention to protein intake
  • Combination amplifies GI effects of each component

Lifestyle Factors

  • Adequate hydration and 7–9 h of sleep are standard controls in most research protocols.
  • Consistent dose timing improves the reliability of any self-tracked endpoints.
  • Maintain a clean, sterile workflow for every draw to avoid contamination.

Injection Technique

  1. 1Wash hands, then prep the vial top and the target site with separate alcohol swabs.
  2. 2Pinch a subcutaneous skin fold (abdomen, ~2 inches from the navel) and insert at 45–90°.
  3. 3Depress the plunger slowly over 3–5 seconds, hold 5 seconds, then withdraw.
  4. 4Rotate sites each administration and dispose of the syringe in a sharps container.

Frequently Asked Questions

Third-party HPLC testing

CG Labz Verified Batches

No published batches yet.

Research Disclaimer

All compounds are supplied strictly for laboratory research. Dosing figures below summarize ranges reported in published preclinical and clinical literature for reference purposes only. CG Labz does not provide medical advice or individualized dosing recommendations.

Peer-reviewed literature

References

  1. [1] New England Journal of Medicine
    Enebo L.B. et al. Cagrilintide plus semaglutide for obesity.
    View Source